43 related articles for article (PubMed ID: 9395715)
1. Cathepsin B-inhibitor promotes the development of Th1 type protective T cells in mice infected with Leishmania major.
Maekawa Y; Himeno K; Katunuma N
J Med Invest; 1997 Aug; 44(1-2):33-9. PubMed ID: 9395715
[TBL] [Abstract][Full Text] [Related]
2. Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis.
Maekawa Y; Himeno K; Ishikawa H; Hisaeda H; Sakai T; Dainichi T; Asao T; Good RA; Katunuma N
J Immunol; 1998 Sep; 161(5):2120-7. PubMed ID: 9725203
[TBL] [Abstract][Full Text] [Related]
3. Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major.
Zhang T; Maekawa Y; Yasutomo K; Ishikawa H; Fawzy Nashed B; Dainichi T; Hisaeda H; Sakai T; Kasai M; Mizuochi T; Asao T; Katunuma N; Himeno K
Biochem Biophys Res Commun; 2000 Sep; 276(2):693-701. PubMed ID: 11027533
[TBL] [Abstract][Full Text] [Related]
4. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
5. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
6. Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection.
Satoskar AR; Stamm LM; Zhang X; Satoskar AA; Okano M; Terhorst C; David JR; Wang B
J Immunol; 1999 Jun; 162(11):6747-54. PubMed ID: 10352294
[TBL] [Abstract][Full Text] [Related]
7. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9?
Li Y; Ishii K; Hisaeda H; Hamano S; Zhang M; Nakanishi K; Yoshimoto T; Hemmi H; Takeda K; Akira S; Iwakura Y; Himeno K
Gene Ther; 2004 Jun; 11(11):941-8. PubMed ID: 14985787
[TBL] [Abstract][Full Text] [Related]
8. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin L is crucial for a Th1-type immune response during Leishmania major infection.
Onishi K; Li Y; Ishii K; Hisaeda H; Tang L; Duan X; Dainichi T; Maekawa Y; Katunuma N; Himeno K
Microbes Infect; 2004 Apr; 6(5):468-74. PubMed ID: 15109961
[TBL] [Abstract][Full Text] [Related]
10. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.
Gabaglia CR; Pedersen B; Hitt M; Burdin N; Sercarz EE; Graham FL; Gauldie J; Braciak TA
J Immunol; 1999 Jan; 162(2):753-60. PubMed ID: 9916695
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of isoprinosine in genetically susceptible BALB/c mice infected with Leishmania major.
Cillari E; Dieli M; Lo Campo P; Sireci G; Caffarelli A; Maltese E; Millott S; Milano S; Liew FY
Immunology; 1991 Sep; 74(1):25-30. PubMed ID: 1718853
[TBL] [Abstract][Full Text] [Related]
13. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection.
Arinola OG; Louis JS; Tacchini-Cottier F; Aseffa A; Salimonu LS
Afr J Med Med Sci; 2005 Mar; 34(1):65-70. PubMed ID: 15971557
[TBL] [Abstract][Full Text] [Related]
15. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
[TBL] [Abstract][Full Text] [Related]
16. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.
Stamm LM; Räisänen-Sokolowski A; Okano M; Russell ME; David JR; Satoskar AR
J Immunol; 1998 Dec; 161(11):6180-8. PubMed ID: 9834104
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
18. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains.
Noben-Trauth N; Paul WE; Sacks DL
J Immunol; 1999 May; 162(10):6132-40. PubMed ID: 10229856
[TBL] [Abstract][Full Text] [Related]
19. [A fraction derived from non-protector extract of Leishmania infantum protects Balb/c mice against Leishmania major infection].
Rolland L; Mookambeswaran Vijayalakshmi SV
C R Acad Sci III; 1993 Nov; 316(11):1342-9. PubMed ID: 8087613
[TBL] [Abstract][Full Text] [Related]
20. Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice.
Zhang T; Maekawa Y; Sakai T; Nakano Y; Ishii K; Hisaeda H; Dainichi T; Asao T; Katunuma N; Himeno K
Int Immunol; 2001 Aug; 13(8):975-82. PubMed ID: 11470767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
